[go: up one dir, main page]

CL2020002252A1 - Formulación oftálmica. - Google Patents

Formulación oftálmica.

Info

Publication number
CL2020002252A1
CL2020002252A1 CL2020002252A CL2020002252A CL2020002252A1 CL 2020002252 A1 CL2020002252 A1 CL 2020002252A1 CL 2020002252 A CL2020002252 A CL 2020002252A CL 2020002252 A CL2020002252 A CL 2020002252A CL 2020002252 A1 CL2020002252 A1 CL 2020002252A1
Authority
CL
Chile
Prior art keywords
ophthalmic formulation
ophthalmic
active compound
pharmaceutically active
aqueous solubility
Prior art date
Application number
CL2020002252A
Other languages
English (en)
Inventor
Stefan Sperl
Franz Obermayr
Original Assignee
Panoptes Pharma Ges M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptes Pharma Ges M B H filed Critical Panoptes Pharma Ges M B H
Publication of CL2020002252A1 publication Critical patent/CL2020002252A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composición oftálmica que comprende un compuesto farmacéuticamente activo oftálmico y albúmina, en la que la solubilidad acuosa del compuesto farmacéuticamente activo aumenta en al menos un 10 % en presencia de albúmina en comparación con la solubilidad acuosa del mismo.
CL2020002252A 2018-03-09 2020-08-31 Formulación oftálmica. CL2020002252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18160981 2018-03-09

Publications (1)

Publication Number Publication Date
CL2020002252A1 true CL2020002252A1 (es) 2021-04-30

Family

ID=61622364

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002252A CL2020002252A1 (es) 2018-03-09 2020-08-31 Formulación oftálmica.

Country Status (15)

Country Link
US (1) US20210052737A1 (es)
EP (1) EP3761960B1 (es)
JP (1) JP7081850B2 (es)
KR (1) KR102496934B1 (es)
CN (1) CN111163757B (es)
AU (1) AU2019232153B2 (es)
BR (1) BR112020017988A2 (es)
CA (1) CA3092234A1 (es)
CL (1) CL2020002252A1 (es)
ES (1) ES2972099T3 (es)
IL (1) IL276918B2 (es)
MX (1) MX2020009235A (es)
PL (1) PL3761960T3 (es)
WO (1) WO2019170848A1 (es)
ZA (1) ZA202005233B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900022881A1 (it) * 2019-12-03 2021-06-03 Ntc Srl Budesonide per uso oftalmico in un metodo di trattamento dell’occhio
CN112933075A (zh) * 2019-12-11 2021-06-11 刘力 局部给药的葛根相关药物组合物
IL307559A (en) 2021-04-09 2023-12-01 Immunic Ag Deuterated dihydroorotate dihydrogenase (DHODH) inhibitors
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물
CN114577957A (zh) * 2021-12-21 2022-06-03 益诺思生物技术南通有限公司 一种虹膜中伏立康唑药物的检测方法
AU2022422334A1 (en) 2021-12-23 2024-06-13 Immunic Ag Dhodh inhibitors containing a carboxylic acid bioisostere
US20230278979A1 (en) * 2022-03-01 2023-09-07 Kiora Pharmaceuticals Gmbh Salts of a dihydroorotate dehydrogenase (dhod) inhibitor
WO2025003402A1 (en) 2023-06-28 2025-01-02 Immunic Ag Heteroaromatic dhodh inhibitors
CN116687840B (zh) * 2023-08-03 2023-10-20 四川省医学科学院·四川省人民医院 一种用于治疗眼部病状的凝胶制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
WO1997039769A1 (fr) * 1996-04-19 1997-10-30 R-Tech Ueno, Ltd. Composition de medicament comprenant de l'albumine en tant que principe actif
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
CA2558509C (en) * 2004-03-11 2011-11-22 Actelion Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
EP3139914B1 (en) 2014-05-08 2023-07-26 Kiora Pharmaceuticals GmbH Compounds for treating ophthalmic diseases and disorders

Also Published As

Publication number Publication date
MX2020009235A (es) 2023-01-16
AU2019232153A1 (en) 2020-09-10
JP2021515777A (ja) 2021-06-24
PL3761960T3 (pl) 2024-04-15
CN111163757B (zh) 2022-04-19
CA3092234A1 (en) 2019-09-12
ES2972099T3 (es) 2024-06-11
WO2019170848A1 (en) 2019-09-12
BR112020017988A2 (pt) 2020-12-22
KR102496934B1 (ko) 2023-02-06
IL276918A (en) 2020-10-29
CN111163757A (zh) 2020-05-15
EP3761960A1 (en) 2021-01-13
IL276918B1 (en) 2024-06-01
AU2019232153B2 (en) 2023-07-13
US20210052737A1 (en) 2021-02-25
JP7081850B2 (ja) 2022-06-07
KR20200130280A (ko) 2020-11-18
EP3761960B1 (en) 2023-11-22
IL276918B2 (en) 2024-10-01
EP3761960C0 (en) 2023-11-22
ZA202005233B (en) 2022-02-23

Similar Documents

Publication Publication Date Title
CL2020002252A1 (es) Formulación oftálmica.
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2018000285A (es) Composicion para desobstruir la nariz congestionada que tiene actividad antiviral.
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
AR098168A1 (es) Formulación estable de insulina glulisina
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
EA201690810A1 (ru) Мягкие пастилки, содержащие экстракт куркумы
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CO2018007810A2 (es) Formulación líquida estable de gonadotropina
PH12019502676A1 (en) Moisturizing topical preparation
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
EP4364810A3 (en) Topical formulations and uses thereof
BR112017014295A2 (pt) composição farmacêutica.
AR078167A1 (es) Dispersion solida que comprende un agente anti-vih
CO2020002287A2 (es) Composiciones farmacéuticas
EA201992296A1 (ru) Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета
CO2017000354A2 (es) Desmopresina estabilizada